country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992553

Copy Link Print Information

PF-07257876

PF-07257876 is a CD47/PD‑L1 bispecific antibody that preferentially targets tumor cells through high PD-L1 affinity and weak CD47 affinity. PF‑07257876 simultaneously blocks the CD47‑SIRPα innate immune checkpoint and the PD‑L1/PD‑1 adaptive immune checkpoint, activates dendritic cells and macrophages, enhances CD8⁺ T cell infiltration within the tumor microenvironment, and synergistically mobilizes innate and adaptive immunity to exert antitumor effects. PF-07257876 can be used in research on CD47/PD‑L1-related cancers, such as ovarian cancer and non-small cell lung cancer.

For research use only. We do not sell to patients.

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PF-07257876 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Species Reactivity
- In Vitro
- Target
- Conjugated
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Species Reactivity

Human

In Vitro

PF-07257876 exhibits high affinity for PD-L1 and weaker affinity for CD47, thereby achieving tumor-biased targeting and reducing off-target binding to red blood cells^[1]^[2].
PF‑07257876 can dually inhibit the CD47‑SIRPα and PD‑L1‑PD‑1 immune checkpoint axes, activate dendritic cells and macrophages, enhance CD8⁺ T cell infiltration in the tumor microenvironment, and generate an innate‑adaptive combined antitumor immune response^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Target

CD47 & PDL1

Conjugated

Unconjugated

Application

ELISA, FACS, Functional assay

Chemical Information

SMILES

[PF- 07257876]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Luo X, et al. Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer. Cancer control : journal of the Moffitt Cancer Center. 2023;30:10732748231159706.

[2]. Jiang C, et al. Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives. Frontiers in oncology. 2024;14:1378647.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote